Retinoblastoma
Oncology·MeSH: Retinoblastoma
Prevalence
0.1 / 100K
6 drugs in development·2 companies·5 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| cyclophosphamide | NEXUS BIOPHARMA INC (NEXS) |
Phase 3(1)
| Drug | Company |
|---|---|
| Melphalan | ENANTA PHARMACEUTICALS INC (ENTA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Retinoblastoma?
BioSniper tracks 6 drugs in development for Retinoblastoma across 2 companies.
How many clinical trials target Retinoblastoma?
There are 5 clinical trials targeting Retinoblastoma tracked by BioSniper.
What is the prevalence of Retinoblastoma?
The estimated prevalence of Retinoblastoma is approximately 0.1 per 100,000 population.
Deep-dive into Retinoblastoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis